Rosetta Genomics to Appoint Dr. Yitzhak Peterburg to its Board of Directors
Former CEO of Clalit Health Services Brings Deep Healthcare Industry Experience
PHILADELPHIA and REHOVOT, Israel, Nov. 8, 2012 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced summoning of a shareholders meeting for the purpose of approving the appointment of Yitzhak Peterburg, M.D., Dr.P.H., MSc. (age 61) to its Board of Directors. Upon approval of this addition by the Company's shareholders, the Company's Board will consist of seven members.
Dr. Peterburg is a well-regarded pharmaceutical executive and entrepreneur with deep healthcare industry experience. He has served on the Board of TEVA Pharmaceuticals from 2009-2010 and from 2010-2011 served as its Senior Vice President, Head of Global Branded Products, with responsibility for branded products, R&D, business development and in-licensing, after which, he returned to his current Board position at TEVA.
From 1990-2002 Dr. Peterburg was with Clalit Health Services, a non-governmental, not-for-profit organization that provides comprehensive health services to more than 55% of the Israeli population; Clalit Health Services has an annual budget exceeding $3.5 billion and more than 45,000 employees. From 1997 to 2002 he served as General Manager (CEO) for Clalit Health Services and from 1990 to 1997 he held a series of senior executive positions including Head, Health Policy Division and Chief Information Officer, Medical Division. Among his many positions at Clalit, from 1995-1997, Dr. Peterburg served as CEO of Soroka University Medical Center, Beer-Sheba, Israel, one of the biggest university hospitals in Israel.
Following his tenure at Clalit, Dr. Peterburg was President and CEO of Cellcom, one of Israel's leading cellular companies, which provides advanced voice and data services to 2.5 million customers, where he managed a $ 1.4 billion annual budget and oversaw 4,000 employees.
"Dr. Peterburg is a tremendous addition to our Board of Directors," said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "His extensive experience with branded pharmaceutical products combined with his years of healthcare economics and healthcare policy experience as General Manager of Clalit, position him as a valued adviser to guide the development of Rosetta Genomics into a leader in molecular diagnostics and personalized medicine."
Dr. Peterburg received his M.D. degree from Hadassah Medical School in Jerusalem and is board-certified in Pediatrics and Health Services Management. He holds a Dr.P.H. in Health Administration from Columbia University and an MSc degree in Information Systems from the London School of Economics. Dr. Peterburg is a Professor in the School of Business, Ben-Gurion University, Beer-Sheba.
About miRview® Products
miRview® are a series of microRNA-based diagnostic products offered by Rosetta Genomics. miRview® mets² accurately identifies the primary tumor type in primary and metastatic cancer including CUP. miRview® meso diagnoses mesothelioma, a cancer connected to asbestos exposure. miRview® lung accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. miRview® kidney accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma. miRview® tests are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview® mets² test, 60,000 from miRview® meso, 54,000 from miRview® kidney and 226,000 patients from miRview® lung. The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.mirviewdx.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.
About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000 Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's miRview® product line is commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to Dr. Peterburg's abilities to help guide the development of Rosetta into a leader in molecular diagnostics and personalized medicine and Rosetta's capitalization of its microRNA platform constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2011 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
SOURCE Rosetta Genomics Ltd.
Get content for your website
Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.